-
J.
Swazey
(1974)
Chlorpromazine in Psychiatry: A Study of Therapeutic Innovation
-
S.
Dencker
(1976)
High-dose Treatment with Neuroleptics in the Acute Phase of Mental Disease
Journal of the Royal Society of Medicine, 69
-
Sheng
Wang,
T.
Che,
A.
Levit,
B.
Shoichet,
Daniel
Wacker,
B.
Roth
(2018)
STRUCTURE OF THE D2 DOPAMINE RECEPTOR BOUND TO THE ATYPICAL ANTIPSYCHOTIC DRUG RISPERIDONE
Nature, 555
-
B.
Kinon,
J.
Lieberman
(1996)
Mechanisms of action of atypical antipsychotic drugs: a critical analysis
Psychopharmacology, 124
-
R.
Kahn,
W.
Fleischhacker,
H.
Boter,
M.
Davidson,
Y.
Vergouwe,
Ireneus
Keet,
M.
Gheorghe,
Janusz
Rybakowski,
S.
Galderisi,
J.
Libiger,
M.
Hummer,
S.
Dollfus,
J.
López-Ibor,
L.
Hranov,
W.
Gaebel,
J.
Peuskens,
N.
Lindefors,
A.
Riecher-Rössler,
D.
Grobbee
(2008)
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial
The Lancet, 371
-
P.
Tyrer
(2011)
Has the closure of psychiatric beds gone too far? Yes
BMJ : British Medical Journal, 343
-
(1964)
NIMH - psychopharmacology service center collaborative study group . Phenothiazine treatment in acute schizophrenia
-
D.
Owens
(2012)
Meet the relatives: a reintroduction to the clinical pharmacology of ‘typical’ antipsychotics (Part 2)
Advances in Psychiatric Treatment, 18
-
J.
Idänpään-Heikkilä,
E.
Alhava,
M.
Olkinuora,
I.
Palva
(1975)
CLOZAPINE AND AGRANULOCYTOSIS
The Lancet, 306
-
SolomonH
Snyder
(1976)
The dopamine hypothesis of schizophrenia: focus on the dopamine receptor.
The American journal of psychiatry, 133 2
-
Paul
Ash
(2000)
Electrodiagnostic studies in ulnar neuropathy at the elbow.
Neurology, 54
-
S.
Leucht,
Werner
Kissling,
J.
Davis
(2009)
Second-generation antipsychotics for schizophrenia: can we resolve the conflict?
Psychological Medicine, 39
-
J.
Elkes,
C.
Elkes
(1954)
Effect of Chlorpromazine on the Behaviour of Chronically Overactive Psychotic Patients
British Medical Journal, 2
-
S.
Leucht,
S.
Heres,
J.
Hamann,
J.
Kane
(2007)
Methodological issues in current antipsychotic drug trials.
Schizophrenia bulletin, 34 2
-
C.
Owens
(1999)
A Guide to the Extrapyramidal Side-effects of Antipsychotic Drugs: Involuntary movements and schizophrenia:a limitation to the concept of tardive dyskinesia?
-
CreeseI,
BurtDR,
SnyderSH
(1976)
Dopamine receptor binding predicts clinical and pharmacological potencies or antischizophrenic drugs
Science, 192
-
Wayne
Beer
(2000)
Book Review: Panic Disorder: Clinical Diagnosis, Management and Mechanisms
Australian and New Zealand Journal of Psychiatry, 34
-
R.
Girgis,
Anthony
Zoghbi,
D.
Javitt,
J.
Lieberman
(2019)
The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: A critical and comprehensive review.
Journal of psychiatric research, 108
-
Peter
Jones,
T.
Barnes,
L.
Davies,
G.
Dunn,
H.
Lloyd,
K.
Hayhurst,
R.
Murray,
A.
Markwick,
S.
Lewis
(2006)
Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Archives of general psychiatry, 63 10
-
J.
Krystal,
L.
Karper,
J.
Seibyl,
G.
Freeman,
R.
Delaney,
J.
Bremner,
G.
Heninger,
M.
Bowers,
D.
Charney
(1994)
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
Archives of general psychiatry, 51 3
-
P.
Seeman,
M.
Chau-Wong,
J.
Tedesco,
K.
Wong
(1975)
Brain receptors for antipsychotic drugs and dopamine: direct binding assays.
Proceedings of the National Academy of Sciences of the United States of America, 72 11
-
J.
Geddes,
N.
Freemantle,
P.
Harrison,
P.
Bebbington
(2000)
Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis
BMJ : British Medical Journal, 321
-
S.
Kapur,
R.
Zipursky,
P.
Roy,
Corey
Jones,
G.
Remington,
K.
Reed,
S.
Houle
(1997)
The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study
Psychopharmacology, 131
-
(1952)
Un nouveau stabilisateur vegetatif
-
D.
Wong,
H.
Wagner,
L.
Tune,
R.
Dannals,
G.
Pearlson,
J.
Links,
C.
Tamminga,
E.
Broussolle,
E.
Broussolle,
H.
Ravert,
A.
Wilson,
Thomas
Toung,
J.
Malát,
Jeffery
Williams,
L.
O'Tuama,
S.
Snyder,
M.
Kuhar,
M.
Kuhar,
A.
Gjedde,
A.
Gjedde
(1986)
Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics.
Science, 234 4783
-
I.
Creese,
D.
Burt,
SolomonH
Snyder
(1976)
Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs
Science, 192
-
H.
Haase
(1961)
Extrapyramidal modification of fine movements: a "conditio sine qua non" of the fundamental therapeutic action of neuroleptic drugs.
Revue canadienne de biologie, 20
-
(1957)
Characteristique neurophysiologique des medicaments neuroleptiques . Rapport symposium internationale medicaments neuroleptiques psychotropies
-
D.
Fischer-Barnicol,
S.
Lanquillon,
E.
Haen,
P.
Zöfel,
H.
Koch,
M.
Dose,
H.
Klein
(2008)
Typical and Atypical Antipsychotics – The Misleading Dichotomy
Neuropsychobiology, 57
-
J.
Lieberman,
T.
Stroup,
J.
McEvoy,
J.
McEvoy,
M.
Swartz,
R.
Rosenheck,
D.
Perkins,
R.
Keefe,
S.
Davis,
C.
Davis,
B.
Lebowitz,
J.
Severe,
J.
Hsiao
(2005)
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
The New England journal of medicine, 353 12
-
J.
Kane,
G.
Honigfeld,
J.
Singer,
H.
Meltzer
(1988)
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.
Archives of general psychiatry, 45 9
-
RosebushPI,
MazurekMF
(1999)
Neurologic side-effects in neuroleptic-naïve patients treated with haloperidol and risperidone
Neurology, 52
-
P.
Seeman,
T.
Tallerico
(1998)
Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors
Molecular Psychiatry, 3
-
D.
Owens
(2014)
A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs by D. G. Cunningham Owens
-
D.
Owens
(2008)
How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia
Advances in Psychiatric Treatment, 14
-
O.
Howes,
S.
Kapur
(2009)
The dopamine hypothesis of schizophrenia: version III--the final common pathway.
Schizophrenia bulletin, 35 3
-
R.
Rosenheck,
D.
Perlick,
S.
Bingham,
Wen
Liu-Mares,
J.
Collins,
S.
Warren,
D.
Leslie,
E.
Allan,
E.
Campbell,
S.
Caroff,
J.
Corwin,
Lori
Davis,
R.
Douyon,
L.
Dunn,
D.
Evans,
E.
Frecska,
J.
Grabowski,
D.
Graeber,
L.
Herz,
K.
Kwon,
W.
Lawson,
F.
Mena,
J.
Sheikh,
D.
Smelson,
V.
Smith‐Gamble
(2003)
Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
JAMA, 290 20
-
P.
Donlon,
J.
Hopkin,
J.
Tupin,
J.
Wicks,
M.
Wahba,
A.
Meadow
(1980)
Haloperidol for acute schizophrenic patients. An evaluation of three oral regimens.
Archives of general psychiatry, 37 6
-
E.
Johnstone,
C.
Frith,
T.
Crow,
M.
Carney,
J.
Price
(1978)
MECHANISM OF THE ANTIPSYCHOTIC EFFECT IN THE TREATMENT OF ACUTE SCHIZOPHRENIA
The Lancet, 311
-
M.
Huttunen
(1995)
The Evolution of the Serotonin‐Dopamine Antagonist Concept
Journal of Clinical Psychopharmacology, 15
-
P.
Oosthuizen,
R.
Emsley,
J.
Turner,
N.
Keyter
(2001)
Determining the optimal dose of haloperidol in first-episode psychosis
Journal of Psychopharmacology, 15
-
Sonia
Johnson
(2011)
Has the closure of psychiatric beds gone too far? No
BMJ : British Medical Journal, 343
-
J.
Hyttel,
J.
Larsen,
A.
Christensen,
J.
Arnt
(1985)
Receptor-binding profiles of neuroleptics.
Psychopharmacology. Supplementum, 2
-
H.
Hippius
(1999)
A historical perspective of clozapine.
The Journal of clinical psychiatry, 60 Suppl 12
-
D.
Javitt,
S.
Zukin
(1991)
Recent advances in the phencyclidine model of schizophrenia.
The American journal of psychiatry, 148 10
-
D.
Naber,
M.
Lambert
(2009)
The CATIE and CUtLASS Studies in Schizophrenia
CNS Drugs, 23
-
J.
Goldstein
(2000)
The new generation of antipsychotic drugs: how atypical are they?
The international journal of neuropsychopharmacology, 3 4
-
P.
Silverstone,
A.
Ravindran
(1999)
Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.
The Journal of clinical psychiatry, 60 1
-
(1988)
Clozapine for treatmentresistant schizophrenia
-
Stephen
Ilyas,
J.
Moncrieff
(2012)
Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010.
The British journal of psychiatry : the journal of mental science, 200 5
-
R.
McCreadie,
Ian
MacDonald
(1977)
High Dosage Haloperidol in Chronic Schizophrenia
British Journal of Psychiatry, 131
-
F.
Owen,
T.
Crow,
M.
Poulter,
Alan
Cross,
A.
Longden,
G.
Riley
(1978)
INCREASED DOPAMINE-RECEPTOR SENSITIVITY IN SCHIZOPHRENIA
The Lancet, 312
-
A.
Carlsson,
M.
Lindqvist
(2009)
EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN.
Acta pharmacologica et toxicologica, 20
-
Guttmacher
Ms
(1964)
PHENOTHIAZINE TREATMENT IN ACUTE SCHIZOPHRENIA; EFFECTIVENESS: THE NATIONAL INSTITUTE OF MENTAL HEALTH PSYCHOPHARMACOLOGY SERVICE CENTER COLLABORATIVE STUDY GROUP.
Archives of General Psychiatry, 10
-
A.
Randrup,
I.
Munkvad
(1974)
Pharmacology and physiology of stereotyped behavior.
Journal of psychiatric research, 11
-
S.
Matthysse
(1973)
Antipsychotic drug actions: a clue to the neuropathology of schizophrenia?
Federation proceedings, 32 2